$RGNX

REGENXBIO (NASDAQ:RGNX) expects Q4 pivotal readout for sura-vec, a gene therapy for wet AMD. Trials compare sura-vec against ranibizumab and aflibercept, with primary endpoint being change in best-corrected visual acuity at 54 weeks. Earlier data showed reduced treatment burden and maintained vision. No drug-related serious adverse events reported. Company's manufacturing facility can produce up to 350,000 annual doses. Commercial success depends on efficacy, safety, and payer coverage.

REGENXBIO's RGX-202 met the primary end point in a phase 3 trial for Duchenne muscular dystrophy, achieving mean microdystrophin expression exceeding 10% of normal levels at week 12. The study, presented at the 2026 Child Neurology Society Annual Meeting, showed functional improvements in participants. RGX-202 was well tolerated, with common adverse events including vomiting, fatigue, and nausea. The company reported two serious but resolved adverse events.

REGENXBIO's Kenneth T. Mills resigned from the board on October 21, 2026, to focus on his new role as CEO of another company. George Migausky was appointed Chairman, and Daniel Tassé stepped down as Lead Independent Director, per corporate governance guidelines. All changes were effective October 21, 2026.

REGENXBIO Inc. (RGNX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 14, 2026, Kenneth T. Mills resigned from the board of directors (the “Board”) of REGENXBIO Inc. (the “Company”)

JPMorgan Chase & Co. increased its stake in Regenxbio Inc. (RGNX) by 60.82%, acquiring 1,346,746 shares at $7.53 each. The firm now holds 3,560,915 shares, representing 5.30% of its portfolio. RGNX, a clinical-stage biotech, has a market cap of $454.17 million and faces financial distress, with a GF-Score of 53/100 and negative profitability metrics. The stock has declined 77.26% since its IPO and is currently trading at $6.88.

Mizuho initiated Regenxbio with an Outperform rating, citing strong approval potential for its pipeline drugs targeting Duchenne muscular dystrophy, wet age-related macular degeneration, and diabetic retinopathy. The firm set a $22 price target, implying 196% upside.

Mizuho initiated coverage on Regenxbio (NASDAQ:RGNX) with an outperform rating and $22.00 price target, citing its gene therapy pipeline. The stock is down 48% YTD. FDA placed a clinical hold on RGX-121, but the company reported positive Phase 2 data for diabetic retinopathy. Insider buying was also noted.

Three gene therapy programs for neovascular age-related macular degeneration (nAMD) are nearing phase 3 readouts. AbbVie and REGENXBIO's sura-vec (sura-vec) expects phase 3 results by late 2026. 4D Molecular Therapeutics' 4D-150 (4D-150) phase 3 trials are fully enrolled, with results expected in 2027. Adverum Biotechnologies' ixoberogene soroparvovec (ixo-vec) is in phase 3, with one trial fully enrolled.

Regenxbio (RGNX) stock rose 3.5% in pre-market trading after presenting positive three-year data from its Phase II ALTITUDE study. 60% of participants showed clinically meaningful improvement, with no adverse events. Stifel maintained a Buy rating with a $42 price target. The broader market was modestly positive, but Regenxbio's pipeline developments drove the move.

Regenxbio Inc (RGNX) shares rose 4.8% premarket after presenting positive 3-year data for its gene therapy, surabgene lomparvovec, in diabetic retinopathy. The study showed sustained improvement without additional treatment. The company also settled patent litigation with Sarepta Therapeutics for $39.0 million.